DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Luo, Heng, Ping Zhang, Hui Huang, Jialiang Huang, Emily Kao, Leming Shi, Lin He, and Lun Yang. 2014. “DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome.” Nucleic Acids Research 42 (Web Server issue): W46-W52. doi:10.1093/nar/gku433. http://dx.doi.org/10.1093/nar/gku433. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1093/nar/gku433                                                                                                                                                                                                                                     |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepo:13581097                                                                                                                                                                                                                  |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepo:dash.current.terms-of-use#LAA |

**DDI-CPI, a server that predicts drug–drug interactions through implementing the chemical–protein interactome**

Heng Luo⁴,⁵, Ping Zhang⁵,‡, Hui Huang⁴, Jialiang Huang⁴, Emily Kao⁵, Leming Shi⁶, Lin He⁴ and Lun Yang¹,*

¹Bio-X Institutes, Shanghai Jiao Tong University, Shanghai 200030, China, ²University of Arkansas at Little Rock/University of Arkansas for Medical Sciences, Little Rock, AR 72204, USA, ³Healthcare Analytics Research Group, IBM T.J. Watson Research Center, Yorktown Heights, NY 10598, USA, ⁴Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Heath, Boston, MA 02215, USA, ⁵Department of Bioengineering, University of California at Berkeley, Berkeley, CA 94720, USA and ⁶School of Pharmacy, Fudan University, Shanghai 201203, China

Received February 8, 2014; Revised April 20, 2014; Accepted May 3, 2014

ABSTRACT

Drug–drug interactions (DDIs) may cause serious side-effects that draw great attention from both academia and industry. Since some DDIs are mediated by unexpected drug–human protein interactions, it is reasonable to analyze the chemical–protein interactome (CPI) profiles of the drugs to predict their DDIs. Here we introduce the DDI-CPI server, which can make real-time DDI predictions based only on molecular structure. When the user submits a molecule, the server will dock user’s molecule across 611 human proteins, generating a CPI profile that can be used as a feature vector for the pre-constructed prediction model. It can suggest potential DDIs between the user’s molecule and our library of 2515 drug molecules. In cross-validation and independent validation, the server achieved an AUC greater than 0.85. Additionally, by investigating the CPI profiles of predicted DDI, users can explore the PK/PD proteins that might be involved in a particular DDI. A 3D visualization of the drug-protein interaction will be provided as well. The DDI-CPI is freely accessible at http://cpi.bio-x.cn/ddi/.

INTRODUCTION

A recent study indicates that drugs are commonly co-prescribed, and nearly one out of 25 individuals are at risk of a major adverse reaction caused by drug–drug interactions (DDIs), especially in older patients (1). In addition to severe adverse reactions, DDIs may result in early termination of drug developments as well as withdrawal of marketed drugs (2,3). Predicting and discovering DDIs will not only prevent life-threatening consequences in clinical practice, but also prompt safe drug co-prescriptions for better treatments (4,5).

DDIs can be classified into three categories: pharmaceutical, pharmacokinetic (PK) and pharmacodynamic (PD) (6). Pharmaceutical interactions are usually caused by physical or chemical incompatibility among the co-prescribed drugs. PK interactions refer to the perturbations on the absorption, distribution, metabolism or excretion of one another, which are usually mediated by PK proteins (7). PD interactions create antagonistic or synergistic pharmacologic effect of two drugs (8) which may involve unexpected bindings of the drug molecules with the PD proteins, such as target or off-target proteins (9,10). There are published computational methodologies predicting DDIs (4,8,11–17); however, as far as we know, no research has published the prediction model based only on drug structure without requiring additional pharmacological or biological background information of the predicted drug. Also, there are currently no freely available servers for real-time DDI predictions.

As many of the DDIs are mediated by unexpected drug-protein interactions, it is reasonable to utilize such interactome information to make DDI predictions. Therefore, we introduce DDI-CPI, a server predicting drug–drug interactions via chemical–protein interactome (CPI). The CPI is a methodology that utilizes *in silico* simulations to mimic the
were constructed using AutoDock Vina (34) with the ran-
molecules across 611 targetable human protein pockets
ensure a reasonable calculation speed. The minimal docking
implemented rigid docking rather than flexible docking to
dom seed set to 10,000 and other default parameters. We
improved speed and accuracy in comparison to AutoDock
AutoDock Vina is a molecular docking program that has
Preparation of the CPI
in Supplementary Table S2.
sequently, we extracted function annotations for those pro-
3.4 Å (89% of the protein ended up with better resolution
structures, (ii) all structures have better resolution than
tal structures, (ii) all structures have better resolution than
structures, including 239 human PK proteins and 372 PD
The PD proteins were distinct human proteins prepared from the PDBBind database
32), which contains curated crystal structures with binding
pocket information. All the proteins we selected were based
on the following criteria: (i) all proteins have X-ray crys-
tal structures, (ii) all structures have better resolution than
3.4 Å (89% of the protein ended up with better resolution
than 2.5 Å) and (iii) binding pockets were identified around
the embedded ligands in the crystal structure (25, 26). Sub-
sequently, we extracted function annotations for those pro-
teins from UniProtKB (33). The list of proteins is included
in Supplementary Table S2.

Preparation of the library drugs and targets
We collected 2515 library drug molecules (85% are FDA
approved drugs) and annotations with different ionization
states from DrugBank (27) and STITCH (28), and then prepared
their 3D structures via Corina online and Vega ZZ
(29). The list of drugs is attached in Supplementary Table
S1.
We also collected 611 high quality ligand-bindable PDB
structures, including 239 human PK proteins and 372 PD
proteins. The PK proteins were Protein Data Bank (PDB)
(30) structures from a published paper with all available
drug metabolite enzymes (31). The PD proteins were dis-
tinct human proteins prepared from the PDBBind database
(32), which contains curated crystal structures with binding
pocket information. All the proteins we selected were based
on the following criteria: (i) all proteins have X-ray crys-
tal structures, (ii) all structures have better resolution than
3.4 Å (89% of the protein ended up with better resolution
than 2.5 Å) and (iii) binding pockets were identified around
the embedded ligands in the crystal structure (25, 26). Sub-
sequently, we extracted function annotations for those pro-
teins from UniProtKB (33). The list of proteins is included
in Supplementary Table S2.

Preparation of the CPI
AutoDock Vina is a molecular docking program that has
improved speed and accuracy in comparison to AutoDock
and DOCK (34, 35). The docking of all 2515 library drug
molecules across 611 targetable human protein pockets
were constructed using AutoDock Vina (34) with the ran-
dom seed set to 10,000 and other default parameters. We
implemented rigid docking rather than flexible docking to
ensure a reasonable calculation speed. The minimal docking
scores and corresponding docked structures were chosen as
the representative docking results to be displayed later.

The training set for DDI prediction model
We used DrugBank DDIs (27) and obtained 6328 drug
pairs with complete CPI annotations, which was used as the
positive set. According to recent DDI prediction methods
(8, 11), we randomly generated 6328 drug pairs that did not
appear in the positive set as the negative set (Figure 1A). The
DrugBank IDs of the drug pairs involved in the positive
and negative sets are attached in Supplementary Table
S3.

Model training and validation
Docking scores for each drug in the training set were gener-
ated against the 611 library targets (Figure 1B). For each
two drugs in drug pair DPi against target Tj, we calcu-
lated the sum S(DPi, Tj) and absolute value of the differ-
ence AD(DPi, Tj) of their docking scores as features. Since
we have 611 library targets, we could generate 1222 features
for each drug pair DPi. In this way, the training set was con-
verted to a matrix containing 12,656 drug pairs as rows and
1222 features as columns with a final column as a depen-
dent variable (Figure 1C). A logistic regression model was
trained based on this matrix for server-side predictions (Fig-
ure 1D).

To validate our method, we randomly held 50% of the
original training data as an independent validation dataset.
For the rest of them, we applied logistic regression using a
10-fold cross-validation to evaluate their performance. The
model was set up with L2-regularization which gives an
increasing penalty as model complexity increases to pre-
vent overfitting. We repeated the cross-validation experi-
ment 100 times to get a mean and a standard deviation of
the area under receiver operating characteristic curve (AU-
ROC) and the area under precision-recall curve (AUPR).
We calculated the accuracy, precision, sensitivity and speci-
city measures based on a prediction threshold when the
maximum F-score (harmonic mean of precision and recall)
was achieved. Then we evaluated this model on the indepen-
dent validation data. To obtain the accuracy, precision, sen-
sitivity and specificity measures for the independent valida-
tion set, we used the average thresholds selected in the cross-
validation experiments. Since this independent dataset was
not included anywhere in the training, we used it as a gold
standard to compare with other published prediction mod-
els.

INPUT AND OUTPUT
Users are required to submit a molecular file with specific
formats such as mol, mol2, sdf, pdb and SMILES (Fig-
ure 1E). We utilize free tools including OpenBabel (36) and
Autodock Tools (37) to convert the file into PDBQT for-
mat with Gasteiger charges. An example drug molecule is
provided for a quick test. When a user molecule is submit-
ted, the docking scores of this drug toward all targets in
the database is calculated via AutoDock Vina (34) with de-
fault number of poses (eight or more). This process is simi-
lar to the inverse- or reverse-docking approach (21, 25, 38).
Here, only the lowest energy scores with the corresponding poses were selected (Figure 1F) to build the CPI profiles, which were fed to the server-side classification model to predict the DDIs (see Figure 1G for detail). The process time ranges from minutes up to several hours, and an email will be sent to the user upon completion of the task. Users can also track the real-time calculation progress online.

The user will be able to view the following outputs:

(i) DDI probabilities of user’s molecule with 2515 drug molecules in library.

(ii) PK/PD proteins that may be involved in the DDI. The server can visualize the 3D conformation of each drug-protein interactions via Jmol (http://www.jmol.org), with amino acid residues around 6.4 Å of the molecule highlighted.

RESULTS

Model evaluation

The model obtained an AUROC of 0.861 ± 0.001 and AUPR of 0.860 ± 0.001 in the 10-fold cross-validation (accuracy: 0.804 ± 0.002, precision: 0.742 ± 0.010, sensitivity: 0.847 ± 0.013, specificity: 0.772 ± 0.012, R²: 0.386 ± 0.002).

Based on the independent validation data, we compared four prediction methods: (i) P-score that uses side-effect similarities to measure the connection between two drugs (39). (ii) S-score that measures the strength of network connections between drug targets to predict DDIs (8). (iii) LR (S-score and P-score) that integrates P-score and S-score by a Bayesian probabilistic model and achieves superior performance than previous prediction methods (8). (iv) DDI-CPI proposed in this paper that analyzes CPI profile to predict DDIs. The comparisons of receiver operating characteristic (ROC) curves and precision-recall curves are shown in Figure 2 and all evaluation measurements are summarized in Table 1. We could see that the CPI-based method outperformed previously-developed computational methods on different parameters.

Case study: DDI prediction for sertraline

We submitted the drug sertraline to DDI-CPI for a prediction test. The server predicts that sertraline might interact with isocarboxazid, linezolid and naratriptan. Sertraline is a selective serotonin-reuptake inhibitor for antidepressant treatment as well as a substrate of flavin-containing amine oxidase A (MAO-A) (40,41). By investigating the CPI profiles of these predicted DDIs, all of the predicted drugs can rank the MAO-A targets to the top 20% among all library proteins in their score vectors (Figure 3), indicating that these DDIs may be through MAO-A. In fact, literature reported that the three drugs predicted indeed interact with MAO-A and the interactions between sertraline and other three drugs do exist (42–44). This case study demonstrates...
that our server not only predicts DDIs, but also helps uncover part of the mechanisms behind-the-scene by showing the PK/PD proteins that may be involved in the interaction.

**DISCUSSION**

Competition between metabolizing enzyme, transporter, or unexpected off-targets can cause DDIs (7–10,45). Fortunately, **DDI-CPI** server is the first one to provide real-time DDI predictions based only on the interactome of drugs toward a representative collection of PK/PD proteins. It serves as a complementary tool in addition to current methods that offers DDIs suggestions, and could help provide the potential mechanism explanations for any molecules with a given structure. However, as stated before, the DDIs may result from alternative mechanisms other than drug–protein interactions such as pharmaceutical interactions and drug metabolites (46). To ensure the speed of high-throughput calculations, we treated the protein targets as simplified rigid models which are not fully realistic representations (47). This assumption, although justified, could still lead to inaccurate predictions. We are not able to guarantee the docking accuracy of the user’s molecule toward all proteins. Therefore, we recommend users to make the judgment based on the docking scores, the docked positions, and could even validate the binding in a more sophisticated docking or wet labs. Nonetheless, we believe the impact of false docked ligand–protein complexes could be minimized in our DDI predictions. (i) The false positives exist in both positive and negative set, thus the noise can be neutralized during our model training process. (ii) Instead of focusing on single drug–protein interaction, CPI considers the docking score vector of the drug toward all available proteins for decision making, minimizing the impact of outliers.

To evaluate whether the model performance is impacted by structural similarity of the drugs within a pair, we calculated all pairwise Tanimoto coefficients among the 2515 drug molecules in library and excluded those which have Tanimoto coefficient $>0.75$ toward any other molecule. We performed a 10-fold cross-validation on the new training set which contains 1620 positives and 1893 negatives. The model obtained an AUROC of $0.870 \pm 0.002$ and AUPR of $0.860 \pm 0.003$ (accuracy: $0.815 \pm 0.003$, precision: $0.756 \pm 0.014$, sensitivity: $0.861 \pm 0.012$, specificity: $0.780 \pm 0.016$ and $R^2: 0.410 \pm 0.006$), which indicates our model is less likely to be impacted by the structural similarity of the drugs within a pair. A fundamnetal difference between **DDI-CPI** and **DRAR-CPI** (26) is that the object in **DDI-CPI** is drug-pair instead of single drug in **DRAR-CPI**. While **DRAR-CPI** calculates the similarity between drugs, **DDI-CPI** further utilizes the statistical model to predict the probability of a drug pair being the true DDI pair. The feature in **DRAR-CPI** is the docking score of the drug with each protein, while the novel definition for feature in this server is the combination of docking scores between each drug pairs across the entire protein set.

**CONCLUSION**

(i) **DDI-CPI** server can predict DDI potentials between the user’s drug across 2515 drug molecules in library
Figure 3. Visualization of the partial CPI for sertraline and the drug that may have interaction with it. All four drugs ranked the MAO protein structures (2BXR, 2Z5X and 2Z5Y) to the top 20% among all library proteins in their score vectors with the docking scores provided in the figure. Two 3D visualizations shown here for the two cells in CPI matrix were captured from our server.

(85% are FDA approved drugs), which is supported by the prediction results from cross-validations, independent validations and case studies.

(ii) DDI-CPI can suggest putative PK/PD proteins involved in the predicted DDIs, thus could help decipher unknown mechanisms of DDI mediated by unexpected drug–human protein interactions.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We appreciate the helpful suggestions from experts in U.S. FDA. We would like to extend our appreciation to Jian Chen for the help in system administration and database maintenance. We would also like to thank Dr Peter Ertl for his JME and JSME Molecular Editors, and we thank the developers of Jmol and JSMol.

FUNDING

Funding for open access charge: Minwei Meng foundation at Shanghai Jiao Tong University.

Conflict of interest statement. Lun Yang is currently an employee at GSK. However, GSK was not involved in this study, which was only based on his previous work at Shanghai Jiao Tong University. The server is for research purposes only and the authors and their organizations are excluded from all liability for any costs, claims, expenses, charges,
losses, damages or penalties of any kind incurred directly or indirectly arising from the use of this server.

REFERENCES

1. Qato,D.M., Alexander,G.C., Conti,R.M., Johnson,M., Schumm,P. (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *JAMA*, **300**, 2867–2878.
2. Magnus,D., Rodgers,S. and Avery,A.J. (2002) GP’s views on computerized drug interaction alerts: questionnaire survey. *J. Clin. Pharm. Ther.*, **27**, 377–382.
3. Bjorndal,T.D., Callaghan,J.T., Einolf,H.J., Fischer,V., Gan,L., Grimm,S., Kao,J., King,S.P., Miwa,G., Ni,L. et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. *Drug Metab. Dispos.*, **31**, 815–832.
4. Duke,J.D., Han,X., Wang,Z., Subhadarshini,A., Karmik,S.D., Li,X., Hall,S.D., Jin,Y., Callaghan,J.T., Overhage,M.J. et al. (2012) Literature-based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. *PLoS Comput. Biol.*, **8**, e1002614.
5. Beijnen,J.H. and Schellens,J.H. (2004) Drug interactions in oncology. *Br. J. Pharmacol.*, **143**, 71–80.
6. Jia,J., Zhu,F., Ma,X., Cao,Z., Cao,Z.W., Li,Y., Li,Y.X. and Chen,Y.Z. (2009) Mechanisms of drug combinations: interaction and specificity. *Curr. Drug Metab.*, **10**, 436–444.
7. Xie,L., Wang,J. and Bourne,P.E. (2007) In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. *PLoS Comput. Biol.*, **3**, e217.
8. Huang,J., Niu,C., Green,C.D., Yang,L., Mei,H. and Han,J.D. (2013) Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. *PLoS Comput. Biol.*, **9**, e1002998.
9. Rodrigues,A.D. and Lin,J.H. (2001) Screening of drug candidates for their drug–drug interaction potential. *Curr. Opin. Chem. Biol.*, **5**, 396–401.
10. Rekic,D., Roshhammer,D., Mukonzo,J. and Ashton,M. (2011) In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. *Br. J. Clin. Pharmacol.*, **71**, 531–543.
11. von Eichborn,J., Murugueito,M.S., Dunkel,M., Koerner,S., Bourne,P.E. and Preissner,R. (2011) PROMISCUSOUS: a database for network-based drug-repositioning. *Nucleic Acids Res.*, **39**, D1060–D1066.
12. Tatonetti,N.P., Fernald,G.H. and Altman,R.B. (2012) A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. *J. Am. Med. Inform. Assoc.*, **19**, 79–85.
13. Vilar,S., Uriarte,E., Santana,L., Tatonetti,N.P. and Friedman,C. (2013) Detection of drug-drug interactions by modeling interaction profile fingerprints. *PLoS One*, **8**, e8321.
14. Yang,L., Wang,K., Chen,J., Jegga,A.G., Luo,H., Shi,L., Wan,C., Guo,X., Qin,S., He,G. et al. (2011) Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome–clopazine-induced agranulocytosis as a case study. *PLoS Comput. Biol.*, **7**, e1002016.
15. Yang,L., Chen,J., Shi,L., Houdoc,M.P., Wang,K. and He,L. (2010) Identifying unexpected therapeutic targets via chemical-protein interactome. *PLoS One*, **5**, e9568.
16. Chen,Y.Z. and Zhi,D.G. (2001) Ligand-protein inverse docking and application. *Nucleic Acids Research, 2014, Vol. 42, Web Server issue W51.
17. Chen,Y.Z. and Zhi,D.G. (2003) The in silico approach to explain the side effects of CETP inhibitors. *PLoS Comput. Biol.*, **9**, e1000387.
18. Petrie,W.M., Dube,S. and Small,J.G. (1995) Sertraline safety and metabolism in humans: a study of human cytochrome P450 isoforms involved in the metabolism of sertraline. *J. Clin. Psychopharmacol.*, **15**, 847–857.
19. Grimm,S., Kao,J., King,S.P., Miwa,G., Ni,L. et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. *Drug Metab. Dispos.*, **31**, 815–832.
20. Chen,Y.Z. and Zhi,D.G. (2001) Ligand-protein inverse docking and application. *Nucleic Acids Research, 2014, Vol. 42, Web Server issue W51.
21. Li,H., Guo,L., Wang,J., Zhang,H., Yang,K., Yu,K., Luo,X., Zhu,W., Chen,K. and Shen,J. et al. (2006) TarFisDock: a web server for identifying drug targets with docking approach. *Nucleic Acids Res.*, **34**, W219–W224.
22. Roğnan,D. (2013) Proteome-scale docking: myth and reality. *Drug Discov. Today Technol.*, **10**, e403–e409.
23. Wallach,J., Jaitly,N. and Lilien,R. (2010) A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. *PLoS One*, **5**, e2063.
24. Yang,L., Chen,J. and He,L. (2009) Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. *PLoS Comput. Biol.*, **5**, e1000441.
25. Yang,L., Luo,H., Chen,J., Xing,Q. and He,L. (2009) SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. *Nucleic Acids Res.*, **37**, W406–W412.
26. Luo,H., Chen,J., Shi,L., Mikailov,M., Zhu,H., Wang,K., He,L. and Yang,L. (2011) DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. *Nucleic Acids Res.*, **39**, W492–W498.
27. Wishart,D.S., Knox,C., Guo,A.C., Shrivastava,S., Hassanali,M., Stothard,P., Chang,Z. and Woolsey,J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.*, **34**, D668–D672.
28. Kuhn,M., von Mering,C., Campillos,M., Jensen,L.J. and Bork,P. (2008) STITCH: interaction networks of chemicals and proteins. *Nucleic Acids Res.*, **36**, D684–D688.
29. Pedretti,A., Villa,L. and Vistoli,G. (2004) VEGA—an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. *J. Comput. Aided Mol. Des.*, **18**, 167–173.
30. Berman,H.M., Westbrook,J., Fung,Z., Gilliland,G., Bhat,T.N., Weissig,H., Shindyalov,I.N. and Bourne,P.E. (2000) Protein Data Bank. *Nucleic Acids Res.*, **28**, 235–242.
31. Yang,L., Price,E.T., Chang,C.W., Li,Y., Huang,Y., Guo,L., Guo,Y., Kaput,J., Shi,L. and Ning,B. (2013) Gene expression variability in human hepatic drug metabolizing enzymes and transporters. *PLoS One*, **8**, e60368.
32. Wang,R., Fang,X., Lu,Y. and Wang,S. (2004) The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. *J. Med. Chem.*, **47**, 2977–2980.
33. Magrane,M. and Consortium,U. (2011) UniProt Knowledgebase: a hub of integrated protein data. *Database (Oxford)*, **2011**, bar009.
34. Trotta,O. and Olson,A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multitreading. *J. Comput. Chem.*, **31**, 455–461.
35. Houston,D.R. and Walkinshaw,M.D. (2013) Consensus docking: improving the reliability of docking in a virtual screening context. *J. Chem. Inf. Model.*, **53**, 384–390.
36. O’Boyle,N.M., Banck,M., James,C.A., Morley,C., Vandermeersch,T. and Hutchison,G.R. (2011) Open Babel: an open chemical toolbox. *J. Cheminform.*, **3**, 33.
37. Harris,P.M., Huey,R., Lindstrom,W., Sanner,M.F., Belew,R.K., Goodsell,D.S. and Olson,A.J. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J. Comput. Chem.*, **30**, 2785–2791.
38. Harriman,D.J. and Deslonechamps,G. (2004) Reverse-docking as a computational tool for the study of asymmetric organocatalysis. *J. Comput. Aided Mol. Des.*, **18**, 303–308.
39. Campillos,M., Kuhn,M., Gavin,A.C., Jensen,L.J. and Bork,P. (2008) Drug target identification using side-effect similarity. *Science*, **321**, 263–266.
40. Fabre,L.F., Abuzzahab,F.S., Amin,M., Claghorn,J.L., Mendes,J., Petric,W.M., Dubé,S. and Small,J.G. (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. *Biol. Psychiatry*, **38**, 592–602.
41. Wild,M.J., McKillop,D. and Butters,C.J. (1999) Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. *Xenobiotica*, **29**, 847–857.
42. Narita, M., Tsuji, B.T. and Yu, V.L. (2007) Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. *Pharmacotherapy*, 27, 1189–1197.

43. Brannan, S.K., Talley, B.J. and Bowden, C.L. (1994) Sertraline and isocarboxazid cause a serotonin syndrome. *J. Clin. Psychopharmacol.*, 14, 144–145.

44. Sclar, D.A., Robison, L.M. and Skaer, T.L. (2008) Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. *Headache*, 48, 126–129.

45. Shitara, Y., Itoh, T., Sato, H., Li, A.P. and Sugiyama, Y. (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. *J. Pharmacol. Exp. Ther.*, 304, 610–616.

46. Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H. and Yokoi, T. (2000) Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. *Br. J. Clin. Pharmacol.*, 49, 244–253.

47. Takatsuka, Y., Chen, C. and Nikaido, H. (2010) Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. *Proc. Natl. Acad. Sci. U.S.A.*, 107, 6559–6565.